Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Trauma-Wiederbelebung mit Vollblut oder Produkten der Gruppe O mit niedrigem Titer (TROOP)

18. September 2026 aktualisiert von: Jan O. Jansen, University of Alabama at Birmingham

The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.

The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.

The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1100

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35294
        • University of Alabama at Birmingham, UAB Hospital
    • California
      • Los Angeles, California, Vereinigte Staaten, 90033
        • Los Angeles County + University of Southern California (LAC + USC) Medical Center
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70112
        • University Medical Center New Orleans LCMC Health
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University School of Medicine
    • North Carolina
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27157
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45267
        • University of Cincinnati Medical Center
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health and Sciences University Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Penn Presbyterian Medical Center
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • University of Texas Health Science Center Houston
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • University of Texas Health San Antonio and University Health System
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98104
        • Harborview Medical Center
    • Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53226
        • Froedtert Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

15 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)

  2. Patient taken to trauma center directly from scene

  3. Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting

  4. Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol

  5. Traumatic injury with at least one of the following:

    1. Confirmed or suspected acute major bleeding
    2. Assessment of Blood Consumption (ABC) Score ≥2

Exclusion Criteria:

  1. Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
  2. Patients transferred from another hospital
  3. Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
  4. Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
  5. Moribund patients expected to die within 1 hour
  6. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
  7. Patients with known "do not resuscitate" orders prior to randomization
  8. Patients who refuse the administration of blood products
  9. Individuals with a research "opt out" bracelet.
  10. Greater than 20% total body surface area (TBSA) burns
  11. Suspected inhalation injury victims
  12. Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: LTOWB

Participants randomized to receive (Low Titer O Whole Blood [LTOWB])

Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.

Aktiver Komparator: Components

Participants randomized to receive the component blood products.

Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
6-hour Mortality
Zeitfenster: First 6 hours after randomization

Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant)

First 6 hours after randomization

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
24-hour Mortality
Zeitfenster: First 24 hours after randomization

Participant vital status at 24-hours following randomization

First 24 hours after randomization
Hospital/30-day Mortality
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Incidence of Pre-specified Complications
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Adjudicated Primary Cause of Death
Zeitfenster: 30-days post randomization

Primary cause of death as reviewed and determined by the study investigators (consensus)

30-days post randomization
Length of Stay (Hospital and Intensive Care Unit)
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Number of hours hospitalized (includes both hospital and intensive care unit time)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Hospital-, Ventilator- and Intensive Care Unit-free days
Zeitfenster: 30-days post randomization

Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit.

30-days post randomization
Incidence of major surgical procedures
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The proportion of participants undergoing major surgical procedures.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Time to hemostasis in those undergoing procedures with a hemostatic component
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Zeitfenster: First 24 hours after randomization

The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.)

First 24 hours after randomization
Discharge destination
Zeitfenster: At hospital discharge or 30-days post randomization (whichever the earlier)

Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc.

At hospital discharge or 30-days post randomization (whichever the earlier)
Functional status
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Patient's quality of life
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

27. Juli 2023

Primärer Abschluss (Tatsächlich)

4. August 2026

Studienabschluss (Tatsächlich)

4. August 2026

Studienanmeldedaten

Zuerst eingereicht

8. November 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

28. November 2022

Zuerst gepostet (Tatsächlich)

6. Dezember 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. September 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IRB-300010517
  • 1UG3HL157401-01A1 (US NIH Stipendium/Vertrag)
  • 1U24HL157310-01A1 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .